Combined acitretin and Candida antigen versus either agent alone in the treatment of recalcitrant warts
To the Editor: Acitretin in individual case reports and intralesional Candida antigen have shown promising efficacy in the treatment of recalcitrant warts; however, a combination of both agents has not been previously studied.
1,2 Herein, we evaluate the efficacy and adverse effects of this combination therapy versus either agent alone in the treatment of recalcitrant warts.
The study included 108 adult patients presenting with multiple recalcitrant warts (warts of [2 years duration that did not respond to at least 2 different modalities). Patients were divided into 3 equal groups: group A received a combination of acitretin (0.5 mg/kg/day until complete clearance or for a maximum duration of 3 months) and intralesional Candida antigen (0.2 mL at 2-week intervals until complete clearance or for a maximum of 5 sessions), group B received acitretin alone, and group C received intralesional Candida antigen alone.
All patients completed the study. Complete clearance of warts was observed in 24 patients (66.7%) of group A, 14 patients (38.9%) of group B, and 12 patients (33.3%) of group C (Fig 1, A-C ). There was a statistically significant difference in the therapeutic response between the combination therapy group and the other 2 groups. Adverse effects were mild or transient and included pain during injection, itching, edema, flu-like symptoms, and cheilitis. After a 6-month follow-up period, recurrence of warts was observed in 4 patients of isolated acitretin group. Due to the relatively high incidence of wart recalcitrance and the frequent recurrence associated with the use of monotherapies, attempts have been made to combine therapies to increase the efficacy, decrease the adverse effects, and reduce the recurrence rate. 3 In the combined acitretin and Candida antigen group, complete clearance of warts was achieved in 66.7% of the studied patients. In the acitretin alone group, complete clearance was achieved in 38.9% of the patients. In the Candida antigen group, complete response was achieved in 33.3% of the patients. This rate of success was lower than that reported by many other authors, 1,4 a finding that might be attributed to differences in the number of studied patients and the type of treated warts.
The superiority of the combination therapy over either agent alone might be attributed to the combined effects of both acitretin and Candida antigen. Candida antigen injection stimulates the production of T helper 1 cytokines that activate cytotoxic and natural killer cells to eradicate human papilloma virus infection. 5 Acitretin modulates epithelial cell J AM ACAD DERMATOL VOLUME 79, NUMBER 2 Research Letters 377 differentiation and proliferation and consequently inhibits the replication and assembly of human papilloma virus within the affected cells. Furthermore, acitretin has potent immunomodulatory and apoptotic effects that might play a role in this respect. 2 Recurrence was only reported in 4 patients of the acitretin alone group. This represents a disadvantage of wart therapy by acitretin, which acts through regulation of keratinocyte differentiation and proliferation, a process that might be reversed after discontinuation of therapy. 2 In conclusion, acitretin combined with Candida antigen is a promising, effective, and safe modality for the treatment of multiple recalcitrant warts and is superior to either agent alone.
